Your session is about to expire
← Back to Search
Triple Therapy for Small Cell Lung Cancer
Study Summary
This trial is studying the best dose of temozolomide to give with niraparib and atezolizumab to treat patients with advanced solid tumors and extensive-stage small cell lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I will use a condom with partners who are pregnant or can become pregnant.I've had a good response to platinum-based chemotherapy after 4-6 cycles.I can start the trial within 7 weeks after my last chemotherapy session.I can take pills and have no allergies to the study drugs.Your blood clotting tests show normal results.I am fully active or can carry out light work.I do not have serious health issues or recent major surgeries that could affect my participation.My cancer type is approved for treatment with atezolizumab by the FDA.I still experience side effects from past treatments, except for hair loss or acceptable lab results.I have an advanced cancer that cannot be cured, and specifically, I have extensive-stage small cell lung cancer for the Phase 2 study.Your blood counts show enough white blood cells, platelets, and hemoglobin to be in good health.My cancer has spread to my brain or its coverings and is getting worse.I have recently had cancer treatment or brain/chest radiation.My kidney and liver tests are within normal limits.My cancer is advanced and cannot be cured with surgery.You have recently used certain medications that stimulate blood cell production, are pregnant, cannot take a PD-1 or PD-L1 inhibitor, have previously received a PARP inhibitor, have not responded well to first-line chemotherapy, or are currently taking a maintenance drug for extensive stage small cell lung cancer.
- Group 1: Arm A (temozolomide, niraparib, atezolizumab)
- Group 2: Arm B (atezolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you provide information regarding any preexisting Quality-of-Life Assessment examinations?
"Currently, the field of Quality-of-Life Assessment has 646 clinical trials in progress; 106 of which are at Phase 3. Though Houston, Texas appears to host most studies for this area of research, there is an impressive 25,766 centres around the world conducting such assessments."
What is the enrollment capacity of this clinical investigation?
"Affirmative. Clinical information hosted on clinicaltrials.gov demonstrates that this particular medical experiment is presently enrolling patients, with the initial posting date being 6th March 2019 and last edited on 2nd July 2022. 74 participants are expected to be recruited from a single centre for study participation."
Are there still vacancies available for participation in this research endeavor?
"Per the information available on clinicaltrials.gov, this investigation is actively seeking participants; it was first posted in March of 2019 and its most recent update occurred on February 7th 2022."
What maladies can Quality-of-Life Assessment be applied to?
"Quality-of-Life Assessment is often used to create and implement advance directives, but it may be useful for treating the symptoms of certain conditions like pharmacotherapy, small cell lung cancer (sclc), or disease progression."
Is this an unprecedented research endeavor?
"Since its initial clinical trial in 2002, sponsored by Schering-Plough with 60 participants, Quality-of-Life Assessment has seen a great deal of research activity. After being approved for Phase 2 trials, 646 live studies are now conducted across 1935 cities and 76 countries."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger